Cytokine and vaccine therapy of kidney cancer.

about

Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine

P2860

Q34675774-D40E39E4-216D-4145-A53F-D8AE1E74D874

P2860

Cytokine and vaccine therapy of kidney cancer.

Item

http://www.wikidata.org/entity/Q35987775

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Cytokine and vaccine therapy of kidney cancer.

@ast

Cytokine and vaccine therapy of kidney cancer.

@en

type

Item

label

Cytokine and vaccine therapy of kidney cancer.

@ast

Cytokine and vaccine therapy of kidney cancer.

@en

prefLabel

Cytokine and vaccine therapy of kidney cancer.

@ast

Cytokine and vaccine therapy of kidney cancer.

@en

P1476

Cytokine and vaccine therapy of kidney cancer.

@en

P2093

Arne Behm

http://www.w3.org/2001/XMLSchema#string

Christian Doehn

http://www.w3.org/2001/XMLSchema#string

Dieter Jocham

http://www.w3.org/2001/XMLSchema#string

Ingo Kausch

http://www.w3.org/2001/XMLSchema#string

Steffi Melz

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial.

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.

Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.

Tumor cell-based vaccination in renal cell carcinoma: rationale. approaches, and recent clinical development.

Prognostic factors of immunotherapy in metastatic renal cell carcinoma.

The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers.

Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.

Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine.

P304

1097-1111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.4.6.1097

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15606336

http://www.w3.org/2001/XMLSchema#string

Cytokine and vaccine therapy of kidney cancer.

about

P2860

P2860

Cytokine and vaccine therapy of kidney cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698